The Wilms tumor suppressor WT1 directs stage-specific quiescence and differentiation of human hematopoietic progenitor cells

EMBO Journal

Volumn 20, Issue 8, 2001, Pages 1897-1909

  Ellisen, Leif W ^a   Carlesso, Nadia ^b   Cheng, Tao ^b   Scadden, David T ^a,b   Haber, Daniel A ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Hematopoiesis; Leukemia; Tumor suppressor; WT1

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; ISOPROTEIN; PROTEIN P21; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR WT1; UNCLASSIFIED DRUG;

ACUTE LEUKEMIA; ARTICLE; CARCINOGENESIS; CELL DIFFERENTIATION; CONTROLLED STUDY; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; NEPHROBLASTOMA; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; RETROVIRUS INFECTION; TUMOR SUPPRESSOR GENE;

BONE MARROW CELLS; CELL DIFFERENTIATION; DNA-BINDING PROTEINS; GENES, TUMOR SUPPRESSOR; GENETIC VECTORS; HEMATOPOIESIS; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKEMIA; MONOCYTES; RETROVIRIDAE; TRANSCRIPTION FACTORS; TRANSFECTION; TUMOR CELLS, CULTURED; WILMS TUMOR; WT1 PROTEINS;

UNIDENTIFIED RETROVIRUS;

EID: 0035901533     PISSN: 02614189     EISSN: None     Source Type: Journal    
DOI: 10.1093/emboj/20.8.1897     Document Type: Article

References (63)

1. A WT1 antisense oligonucleotide inhibits proliferation and induces apoptosis in myeloid leukemia cell lines
2. Expression of the Wilms' tumor gene (WT1) in normal hemopoiesis
3. Mesenchymal to epithelial conversion in rat metanephros is induced by LIF
4. Donor splice-site mutations in WT1 are responsible for Frasier syndrome
5. Functional isolation and characterization of human hematopoietic stem cells
6. High levels of Wilm's tumor gene (WT1) mRNA in acute myeloid leukemia are associated with a worse long-term outcome
7. Patterns of glycosidases in the histiocytic cell line U-937. Effects of agents inducing cell differentiation
8. Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid
9. Notch1-induced delay of human hematopoietic progenitor cell differentiation is associated with altered cell cycle kinetics
10. Temporal mapping of gene expression levels during the differentiation of individual primary hematopoietic cells
11. cip/wafl
12. Purification and expansion of human hematopoietic stem/progenitor cells
13. Expansion in vitro of transplantable human cord blood stem cells demonstrated using a quantitative assay of their lympho-myeloid repopulating activity in non-obese diabetic-scid/scid mice
14. WT1 interacts with the splicing factor U2AF65 in an isoform-dependent manner and can be incorporated into spliceosomes
15. Wilms' tumor gene product WT1 arrests macrophage differentiation of HL-60 cells through its zinc-finger domain
16. Human fetal bone marrow early progenitors for T, B and myeloid cells are found exclusively in the population expressing high levels of CD34
17. Expansion of human cord blood CD34+CD38- cells in ex vivo culture during retroviral transduction without a corresponding increase in SCID repopulating cell (SRC) frequency: Dissociation of SRC phenotype and function
18. WT1 suppresses synthesis of the epidermal growth factor receptor and induces apoptosis
19. Truncated WT1 mutants alter the subnuclear localization of the wild-type protein
20. Induction of p21 by the Wilms' tumor suppressor gene WT1
21. Tumor-associated WT1 missense mutants indicate that transcriptional activation by WT1 is critical for growth control
22. Detection of the WT1 transcript by RT-PCR in complete remission has no prognostic relevance in de novo acute myeloid leukemia
23. Wilms' tumor gene (wt1) expression at diagnosis has no prognostic relevance in childhood acute leukemia treated by an intensive chemotherapy program
24. Cell cycle-related changes in repopulating capacity of human mobilized peripheral blood CD34(+) cells in non-obese diabetic/severe combined immune-deficient mice
25. Alternative splicing and genomic structure of the Wilms tumor gene WT1
26. The genetics of Wilms' tumor - A case of disrupted development
27. Transplantable myeloproliferative disease induced in mice by an interleukin 6 retrovirus
28. Regulation of expression of the CD11b and CD18 subunits of the neutrophil adherence receptor during human myeloid differentiation
29. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia
30. Wilms' tumor gene (WT1) competes with differentiation-inducing signal in hematopoietic progenitor cells
31. Modelling T-cell memory by genetic marking of memory T cells in vivo
32. Mutations in the Wilms' tumor gene WT1 in leukemias
33. CD34: Structure, biology and clinical utility
34. WTI is required for early kidney development
35. 1 phase arrest induced by Wilms tumor protein WT1 is abrogated by cyclin/CDK complexes
36. 0
37. Retention of quiescent hematopoietic cells with high proliferative potential during ex vivo stem cell culture
38. Subnuclear localization of WT1 in splicing or transcription factor domains is regulated by alternative splicing
39. The Wilms tumor suppressor WT1 encodes a transcriptional activator of amphiregulin
40. Zinc finger point mutations within the WT1 gene in Wilms tumor patients
41. The Wilms' tumor gene is expressed in a subset of CD34+ progenitors and downregulated early in the course of differentiation in vitro
42. Presence of Wilms' tumor gene (wt1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias
43. Wilms' tumor gene expression in human CD34+ hematopoietic progenitors during fetal development and early clonogenic growth
44. Expression of the Wilms' tumor gene (WT1) in human leukemias
45. Mutations of the WT1 gene in childhood nonlymphoid hematological malignancies
46. Antagonism of WT1 activity by protein self-association
47. 1 arrest and apoptosis in myeloblastic leukemia cells
48. Sequence and structural requirements for high-affinity binding by the WT1 gene product
49. An in vitro limiting-dilution assay of long-term repopulating hematopoietic stem cells in the mouse
50. Regulated expression of integrins and other adhesion molecules during differentiation of monocytes into macrophages
51. The candidate Wilms' tumour gene is involved in genitourinary development
52. Binding of the Wilms tumor locus zinc finger protein to the EGR-1 consensus sequence
53. WT1-mediated transcriptional activation is inhibited by dominant negative mutant proteins
54. Downregulation of the Wilms' tumor gene (wt1) during myelomonocytic differentiation in HL60 cells
55. Expression of the Wilms' tumor suppressor gene, WT1, is upregulated by leukemia inhibitory factor and induces monocytic differentiation in M1 leukemic cells
56. Expression of the Wilms tumor suppressor gene, WT1, reduces the tumorigenicity of the leukemic cell line MI in C.B-17 scid/scid mice
57. WAF1 expression during normal myeloid differentiation
58. Functional characteristics of individual human hematopoietic stem cells cultured at limiting dilution on supportive marrow stromal layers
59. Constitutive expression of the Wilms' tumor gene (WT1) in the leukemic cell line U937 blocks part of the differentiation program
60. Sequential generations of hematopoietic colonies derived from single nonlineage-committed CD34+CD38- progenitor cells
61. Ex vivo expansion of murine hematopoietic progenitor cells generates classes of expanded cells possessing different levels of bone marrow repopulating potential
62. WAF1/C1P1 expression by p53-independent pathways
63. Rescue of the embryonic lethal hematopoietic defect reveals a critical role for GATA-2 in urogenital development